Clovis raises $130 million IPO
This article was originally published in Scrip
Executive Summary
Clovis Oncology has managed to get its initial public offering away, raising $130 million by selling 10,000,000 shares of its common stock at $13.00 each, the lower range of the filing it made with the US SEC at the start of the month (see: scripintelligence.com, 3 November 2011).
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.